Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 09, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA PRAX-628 Phase 1 study showed consistent safety profile and target engagement in...
August 08, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111) Patients...
June 09, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 ...
June 02, 2023 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
May 24, 2023 06:57 ET | Source: Market.Us

Neurostimulation Devices Market Revenue is Predicted to Surpass a Valuation of US$ 36.5 billion by 2032, States by Market.us

New York, May 24, 2023 (GLOBE NEWSWIRE) -- The Neurostimulation Devices Market stood at US$ 11.1 billion in 2022 and the global market is projected to reach US$ 36.5 billion by 2032. The global...
May 11, 2023 07:30 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
April 19, 2023 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
April 17, 2023 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
February 07, 2023 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline...